ArticleBMC microbiology2026
Molecular identification and biological activity of a red sea bacterial isolate.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine microorganisms residing in the Red Sea have been recognized as valuable sources of novel natural products with potential medical applications. One distinct bacterial isolate coded MMM3 was isolated from the marine tunicate Phallusia nigra, gathered from the Egyptian coast of the Red Sea. The present study aimed to identify and assess the isolated strain’s biological activities. After genomic extraction and PCR amplification, the bacterial strain was identified through 16 S rRNA gene sequencing as Heyndrickxia ginsengihumi and deposited in (NCBI) GenBank database under the accession code PX237387. The tested isolate was cultivated in R2A liquid medium for ten days at 25 °C in a shaking incubator set at 220 rpm. The crude extract exhibited effective COX-2 inhibition and antioxidant activity with IC₅₀ value of 107.07 and 451.75 µg/ml, respectively. The crude extract exerted antifungal effect (inhibition zone of 9 mm) against Candida albicans ATCC 10,231. In addition, the crude extract demonstrated significant cytotoxic activities against HepG2, A-549, MCF-7 and HCT-116 cell lines with IC50 values of 54.67 ± 1.05, 60.19 ± 1.23, 108.79 ± 2.08, and 73.57 ± 1.48 µg/mL, respectively. Regarding the chemical characterization of the crude extract, LC-MS analysis indicated diverse secondary metabolites including linoleic acid, myristoyl glucose-3-phosphate, and 2-acetoxy-4-pentadecylbenzoic acid. The identified metabolites suggest a synergistic contribution to the biological activities of the isolated strain, highlighting its potential as a source of bioactive compounds. The results indicated that the bacteria isolated from Red Sea coast is a promising source of bioactive molecules with medical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.